Skip to main content

Table 2 Results of karyotyping, FISH analysis, mutational screening and BECN1 expression

From: Reductive regulation of BECN1 gene in adult Egyptian patients with do novo AML

Case number Conventional karyotyping FISH results FLT3-ITD/c-Kit/Nucleophosmin mutational status BECN1 expression
1 Normal karyotype t(8;21) Negative FLT3-ITD Positive 0.37(RE)
2 Trisomy 8 t(9;22)Negative   0.13(RE)
3 Normal karyotype 11q23 Negative WT NPM1 0.62(RE)
4 Normal karyotype t(9;22)Negative Mutated NPM1and FLT3-ITD 0.58(RE)
5 t(8;21) Positive t(8;21) Positive cKIT Positive 0.65(RE)
6 Normal karyotype t(8;21) Negative FLT3-ITD Positive 0.18(RE)
7 t(8;21) Positive t(8;21) Positive   1.03(NE)
8 Variable rearrangement t(8;21) Positive cKIT Positive 0.51(RE)
9 17 p deletion t(9;22)Negative   0.33(RE)
10 Normal karyotype t(8;21) Negative FLT3-ITD Positive 0.62(RE)
11 Normal karyotype t(9;22)Negative Mutated NPM1and FLT3-ITD 0.52(RE)
12 Normal karyotype t(9;22)Negative WT NPM1 0.35(RE)
13 t(15;17) Positive t(15;17) Positive   1.04(NE)
14 t(15;17) Positive t(15;17) Positive   1.07(NE)
15 t(9;22) Positive t(9;22) Positive   0.27(RE)
16 Trisomy 8 t(8;21) Negative   0.54(RE)
17 Variable rearrangement t(8;21) Positive cKIT Positive 0.26(RE)
18 t(9;22) Positive t(9;22) Positive FLT3-ITD Positive 0.34(RE)
19 Normal karyotype Inv16 Positive   0.64(RE)
20 t(9;22) Positive t(9;22) Positive   1.05(NE)
21 t(8;21) Positive t(8;21) Positive   1.07(NE)
22 Normal karyotype t(8;21) Negative FLT3-ITD Positive 0.31(RE)
23 t(15;17) Positive t(15;17) Positive   0.29(RE)
24 Trisomy 8 t(8;21) Negative   0.28(RE)
25 Normal karyotype t(9;22) Negative WT NPM1 0.29(RE)
26 Normal karyotype t(9;22) Negative FLT3-ITD Positive 0.31(RE)
27 t(8;21) Positive t(8;21) Positive cKIT Positive 1.02(NE)
28 Normal karyotype t(8;21) Negative FLT3-ITD Positive 0.36(RE)
29 11q23 Positive 11q23 Positive   0.27(RE)
30 Variable rearrangement t(8;21) Positive FLT3-ITD Positive 0.33(RE)
31 Monosomy 7 t(9;22) Negative   1.04(NE)
32 Inv16 Positive Inv16 Positive cKIT Positive 0.26(RE)
33 11q23 Positive 11q23 Positive   0.17(RE)
34 Normal karyotype t(9;22) Negative FLT3-ITD Positive 0.34(RE)
35 Normal karyotype Inv16 Positive   1.04(NE)
36 t(8;21) Positive t(8;21) Positive   1.06(NE)
37 Double Philadelphia t(9;22) Positive   0.29(RE)
38 Normal karyotype t(9;22) Negative FLT3-ITD Positive 0.26(RE)
39 Inv16 Positive Inv16 Positive cKIT Positive 0.32(RE)
40 Normal karyotype Inv16 Negative WT NPM 1.08(NE)
41 Inv16 Positive Inv16 Positive   1.07(NE)
42 t(15;17) Positive t(15;17) Positive   1.03(NE)
43 Normal karyotype t(8;21) Negative FLT3-ITD Positive 0.45(RE)
44 Normal karyotype t(8;21) Negative FLT3-ITD Positive 0.16(RE)
45 t(8;21) Positive t(8;21) Positive cKIT Positive 0.38(RE)
46 t(8;21) Positive t(8;21) Positive cKIT Positive 1.06(NE)
47 Normal karyotype t(8;21) Negative FLT3-ITD Positive 0.43(RE)
48 Normal karyotype Inv16 Negative FLT3-ITD Positive 0.61(RE)
49 t(15;17) Positive t(15;17) Positive   1.04(NE)
50 Normal karyotype t(9;22) Negative WT NPM 0.36(RE)
  1. Data on conventional karyotyping and FLT3-ITD/c-Kit/Nucleophosmin mutational status (in some patients) were obtained from patients medical records
  2. NE normal expression, RE reduced expression, WT wild type, NPM1 Nucleophosmin1, ITD internal tandem duplication.